Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing ‘next-generation cell therapeutics’ - Announces departure of Cenk Sumen as chief scientific officer, but he will remain on advisory board.
Current stock price: 397.50 pence, flat
12-month change: down 14%
Copyright 2024 Alliance News Ltd. All Rights Reserved.